Difference between revisions of "Riechelmann H, et al. Oral. Oncol. (2008) cited as Ref 555 in DOI: 10.1038/s41392-020-0110-5 (Q9818)"

From Wikibase.slis.ua.edu
Jump to navigation Jump to search
(‎Created a new Item: #quickstatements; #temporary_batch_1589975872009)
 
(‎Created claim: Page(s) (P105): 823-829, #quickstatements; #temporary_batch_1590074839150)
 
(8 intermediate revisions by the same user not shown)
Property / First Author string
 +
Riechelmann H
Property / First Author string: Riechelmann H / rank
 +
Normal rank
Property / DOI Identifier
 +
Property / DOI Identifier: 10.1016/j.oraloncology.2007.10.009 / rank
 +
Normal rank
Property / PubMed ID
 +
Property / PubMed ID: 18203652 / rank
 +
Normal rank
Property / Publication Date
 +
2008
Timestamp+2008-01-01T00:00:00Z
Timezone+00:00
CalendarGregorian
Precision1 year
Before0
After0
Property / Publication Date: 2008 / rank
 +
Normal rank
Property / Published In Name String
 +
Oral. Oncol.
Property / Published In Name String: Oral. Oncol. / rank
 +
Normal rank
Property / Volume
 +
44
Property / Volume: 44 / rank
 +
Normal rank
Property / title
 +
Phase I trial with the CD44v6-targeting immunoconjugate bivatuzumab mertansine in head and neck squamous cell carcinoma (English)
Property / title: Phase I trial with the CD44v6-targeting immunoconjugate bivatuzumab mertansine in head and neck squamous cell carcinoma (English) / rank
 +
Normal rank
Property / Page(s)
 +
823-829
Property / Page(s): 823-829 / rank
 +
Normal rank
links / sliswiki / namelinks / sliswiki / name
 +

Latest revision as of 15:45, 21 May 2020

Cited in: "Targeting cancer stem cell pathways for cancer therapy" in Signal Transduct Target Ther; 2020 ; 5 8
Language Label Description Also known as
English
Riechelmann H, et al. Oral. Oncol. (2008) cited as Ref 555 in DOI: 10.1038/s41392-020-0110-5
Cited in: "Targeting cancer stem cell pathways for cancer therapy" in Signal Transduct Target Ther; 2020 ; 5 8

    Statements

    Riechelmann H
    0 references
    0 references
    2008
    0 references
    Oral. Oncol.
    0 references
    44
    0 references
    Phase I trial with the CD44v6-targeting immunoconjugate bivatuzumab mertansine in head and neck squamous cell carcinoma (English)
    0 references
    823-829
    0 references